A trusted drug reference delivers evidence-based guidance, clinical perspectives, and therapeutic recommendations with detailed safety alerts and off-label uses. Featuring updated content on specialty medications, emerging therapies, and pharmacogenomics, it supports optimal patient care and informed medical practice.
AHFS Drug Information® 2026 contains the most dependable drug information available—all in one place. It is the most comprehensive evidence-based source of drug information complete with therapeutic guidelines and off-label uses.
With expanded and revised content supported by more than 97,000 references and incorporating the advice of numerous subject matter experts, AHFS DI helps you protect your patients and your practice.
Updates in the new edition:
- Clinical perspective sections that include place of therapy discussions and recommendations from therapeutic guidelines
- Expanded coverage of specialty medications used to treat a variety of complex, chronic conditions that often require special handling and administration and may require careful oversight to manage severe adverse effects and dosage adjustments
- Contemporary topics such as biosimilars, novel orphan drugs, and updated vaccine guidance based on recommendations from the CDC’s Advisory Committee on Immunization Practices (ACIP) and other authoritative organizations
- Essential drug information content for patient safety including FDA Medwatch alerts, Standardize4Safety concentrations for IV and oral liquid medications, ISMP recommendations, REMS data, BEERS criteria, boxed warnings, and focused updates based on FDA safety findings
- Pharmacogenomic considerations in drug dosing and selection
- Expanded content on new and emerging gene and cellular therapies
- Class-wide revisions to standard and established therapies for common disease states including hypertension and diabetes
- Expanded content on off-label uses, real world data, and long-term clinical data
- New content on new molecular entities (NMEs) and biologic approvals
- New oncology off-label determinations based on reviews by the AHFS Oncology Expert Committee
